Grade 3-5 adverse events were comparable between both treatment groups. Evidence Rating Level: 1 (Excellent) Study Rundown: ...

In the randomized, double-blind, phase 3 study, experts explored treatment with neoadjuvant pembrolizumab (Keytruda) plus chemotherapy, followed by adjuvant pembrolizumab, in patients aged 18 years ...

This study is looking at an immunotherapy treatment called V940 (mRNA-4157) with pembrolizumab to treat melanoma.

Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in ...

The imaging agent Gleolan is only approved for glioma surgery, so the current trial could lead to a new indication. In this ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The KEYNOTE-689 study evaluating pembrolizumab in this patient population met its primary end point of event-free survival.

No new safety concerns were identified with the favezelimab and pembrolizumab combination, and a full data analysis is ongoing. The US drug giant said the study did not meet its primary endpoint ...

For patients with early-stage triple-negative breast cancer, neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab yields a significant improvement in overall survival ...

“Based on our strong phase 2 clinical data reported previously for petosemtamab in HNSCC both as monotherapy and in combination with pembrolizumab, I continue to be confident that petosemtamab ...

The combination statistically significantly improved overall survival, reducing the risk of death by 21% compared with chemotherapy alone. The Food and Drug Administration (FDA) has approved ...